Atai stock forecast.

With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...Company Description. ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive …Stock Price Forecast. The 10 analysts offering 12-month price forecasts for Super Micro Computer Inc have a median target of 397.00, with a high estimate of 500.00 and a low estimate of 240.00 ...Stock Price Forecast The 5 analysts offering 12-month price forecasts for ATAI Life Sciences NV have a median target of 11.00, with a high estimate of 21.00 and a low …Web

On Friday 11/24/2023 the closing price of the ATAI Life Sciences N.V. Registered Shs share was $1.10 on NAS. Compared to the opening price on Friday 11/24/2023 on NAS of $1.12, this is a drop of 1 ...AI is a growth business. Total spending on AI systems is forecast to reach $97.9 billion in 2023, up from $37.5 billion in 2019. For the five-year period ending in 2023, the AI sector is predicted ...U.S. Television Show Ratings Ranking. Ranking is based on ratings data as of Monday, November 20, 2023. The audience figures are derived from the latest Nielsen daily, weekly, or monthly P2+ program audience averages, whichever is the most recently available within the past seven-day window.

Atai Capital believes showing returns net of a 1.50% management fee better reflects actual performance as of 07/12/2023 since no account that Atai Capital currently manages is charged a fee more ...

ATAI Life Sciences N.V. stock price forecast for further price development down to -32.20% (time horizon: 1 day) and price target of 1.11 USD. Short-term (time horizon: 2 weeks) ATAI Life Sciences N.V. share price prediction for 2024-01-12 with daily closed price projectionsMeanwhile, Atai listed on the Nasdaq in June, raising $225 million at a valuation of $2.3 billion. The stock immediately popped 40% but it has since halved in value and Atai's current market cap ...Since Atai Life Sciences is only going public, we don’t have any forecast for the stock. Also, being a clinical-stage company, we don’t have earnings-based metrics to value the stock.NL0015000DX5. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Show more.

Since Atai Life Sciences is only going public, we don’t have any forecast for the stock. Also, being a clinical-stage company, we don’t have earnings-based metrics to value the stock.

24. 3. 2023. ... ... predictions of future events. Although we believe that the ... Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders ...

When is Atai Life Sciences's earnings date? Atai Life Sciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 22nd, 2024 based off last year's report dates. Learn more on ATAI's earnings history.Find real-time SMCI - Super Micro Computer Inc stock quotes, company profile, news and forecasts from CNN Business.RPHM. Reneo Pharmaceuticals Inc. 6.04. +0.10. +1.68%. Get ATAI Life Sciences NV (ATAI:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.30. 8. 2022. ... Wall Street's 12-month median price forecast for ATAI stock stands at $24.50. Compass Pathways (CMPS). magic mushrooms representing champion ...4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the …Web

The social networking company earned $1.28 billion during the quarter, compared to analyst estimates of $1.28 billion. Twitter had a negative net margin of 2.14% and a negative trailing twelve-month return on equity of 0.82%. The firm's revenue was up 37.1% compared to the same quarter last year.That said, analysts are starting to come around on ATAI. H.C. Wainwright biotech analyst Patrick Trucchio maintained a "buy" rating on Atai in early October, with a price target of $20. Its ...How have NBSE shares performed in 2023? NeuBase Therapeutics' stock was trading at $3.8040 on January 1st, 2023. Since then, NBSE stock has decreased by 82.2% and is now trading at $0.6758. View the best growth stocks for 2023 here.Down -34.59% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI) Zacks - Tue Jan 31, 8:35AM CST . atai Life Sciences N.V. (ATAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings... Find the latest TeraWulf Inc. (WULF) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid ...This was the ETF and Ark Invest’s first purchase of ATAI stock since March 14. From March 14 to July 5, ATAI stock declined by 27%. After the recent purchases, ARKG now owns a total of 1.82 ...

May 25, 2023 · These forecasts range from $9 to $20, indicating a considerable increase compared to its previous closing price of $1.88. Over the past 12 months, ATAI’s stock has witnessed a remarkable growth ... Atai Life Sciences. ... Further clinical trial data will create volatility in CMPS stock. COMPASS Pathways 1-year price chart ... registering a CAGR of 16.8% during the forecast period of 2022 to ...

If you want to read our detailed analysis of these stocks, go directly to the 10 Best Psychedelic Stocks to Buy Now. 5. Cybin Inc. (OTC: CLXPF) Cybin Inc. (OTC: CLXPF) stock has returned more than ...As of last trade ATAI Life Sciences NV (ATAI:NMQ) traded at 1.10, 4.76% above its 52-week low of 1.05, set on Oct 27, 2023. Data delayed at least 15 minutes, as of Nov 30 2023 18:35 GMT. Latest ATAI Life Sciences NV (ATAI:NMQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and …Find the latest TeraWulf Inc. (WULF) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid ...Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ouster Inc have a median target of 9.50, with a high estimate of 12.00 and a low estimate of 6.00.SLDP Stock 12 Months Forecast. Based on 3 Wall Street analysts offering 12 month price targets for Solid Power in the last 3 months. The average price target is $3.00 with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 95.44% change from the last price of $1.54.Find the latest CXApp Inc. (CXAI) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid Term ...Mind Medicine (MNMD) is a biotech company that develops psychedelic-inspired therapies for mental health disorders. Find out how analysts rate the stock and what are its growth prospects on TipRanks.com. You can also access the latest earnings reports, forecasts, and price movements of MNMD on the same platform.---Don't miss this opportunity to …LPTX Stock 12 Months Forecast. Based on 3 Wall Street analysts offering 12 month price targets for Leap Therapeutics in the last 3 months. The average price target is $10.00 with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 249.65% change from the last price of $2.86.The team, led by chief investment officer Mike Wilson, agrees that there are clouds on the horizon over the near-term namely because earnings forecasts are down, economic data is weaker, and the ...Atai Life Sciences (ATAI) Stock Forecast & Price Prediction. Estimation of the future price movement of Atai Life Sciences stock, based on various factors such as historical price …Web

NL0015000DX5. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Show more.

Dec 1, 2023 · View atai Life Sciences NV ATAI investment & stock information. Get the latest atai Life Sciences NV ATAI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Dec 1, 2023 · Based on short-term price targets offered by four analysts, the average price target for atai Life Sciences N.V. comes to $13.00. The forecasts range from a low of $6.00 to a high of $20.00. The ... This stake is worth roughly $98M as of Tuesday, March 28, based on COMPASS Pathways’ closing price of $10.23/share on that day. You can find atai’s filed 10-K from last Friday here. With ...Apr 13, 2023 · Validation of atai's operating model and ability to capture value: IPO of COMPASS Pathways in 2020 and licensing deal between Otsuka and atai subsidiary Perception Neuroscience in 2021 Strong cash position of approx. $273M (as of December 31 st , 2022) and access to up to an additional $160m from term loan facility with Hercules 2 lead to ... Company Description. ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive …The average one-year price target for ATAI / ATAI Life Sciences N.V. is $12.572. The forecasts range from a low of $5.151 to a high of $22.05. A stock’s price target is the price at which analysts consider it fairly valued with respect to …Aug 14, 2023 · Atai Life Sciences is forecasted to grow earnings and revenue by 20.7% and 73.6% per annum respectively. EPS is expected to grow by 29.2%. Return on equity is forecast to be -69.3% in 3 years. The average Atai Life Sciences Nv stock price prediction forecasts a potential upside of 1,490.91% from the current ATAI share price of $1.10. What is ATAI's forecast return on equity (ROE) for 2023-2026?View atai Life Sciences NV ATAI investment & stock information. Get the latest atai Life Sciences NV ATAI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Validation of atai's operating model and ability to capture value: IPO of COMPASS Pathways in 2020 and licensing deal between Otsuka and atai subsidiary Perception Neuroscience in 2021 Strong cash position of approx. $273M (as of December 31 st , 2022) and access to up to an additional $160m from term loan facility with Hercules 2 lead to ...Complete ATAI Life Sciences N.V. stock information by Barron's. View real-time ATAI stock price and news, along with industry-best analysis.Their CMPS share price targets range from $19.00 to $120.00. On average, they anticipate the company's stock price to reach $46.83 in the next year. This suggests a possible upside of 683.2% from the stock's current price. View analysts price targets for CMPS or view top-rated stocks among Wall Street analysts.Instagram:https://instagram. balanced index funddostarlimab stockamerican smallcap world ajtaiw stock 3:24 pm. Articles. atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) August 10, 2023 Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients…. August 10, …ATAI Life Sciences. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01 ... api report todayseason three boots ATAI Life Sciences N.V. Watch Set a price target alert Premarket Last Updated: Nov 15, 2023 8:18 a.m. EST Delayed quote $ 1.2900 0.04 2.79% Before Hours Volume: 2.23K …WebATAI – ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are 3 stocks that are looking to commercialize psychedelics for medical use. Investors should keep them on their radars as they have massive long-term potential. Norms and regulations in society can change in the span of … real world portal Down -34.59% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI) Zacks - Tue Jan 31, 8:35AM CST . atai Life Sciences N.V. (ATAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings...SVRA Stock 12 Months Forecast. $6.67. (79.30% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Savara in the last 3 months. The average price target is $6.67 with a high forecast of $7.00 and a low forecast of $6.00. The average price target represents a 79.30% change from the last price of $3.72.